WO2024021740A1 - 皮肤给药控制方法和装置 - Google Patents

皮肤给药控制方法和装置 Download PDF

Info

Publication number
WO2024021740A1
WO2024021740A1 PCT/CN2023/092258 CN2023092258W WO2024021740A1 WO 2024021740 A1 WO2024021740 A1 WO 2024021740A1 CN 2023092258 W CN2023092258 W CN 2023092258W WO 2024021740 A1 WO2024021740 A1 WO 2024021740A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug administration
drug
data
administration
characteristic data
Prior art date
Application number
PCT/CN2023/092258
Other languages
English (en)
French (fr)
Inventor
王梅林
陈刚
Original Assignee
王梅林
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 王梅林 filed Critical 王梅林
Publication of WO2024021740A1 publication Critical patent/WO2024021740A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
    • G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
    • G06F16/24—Querying
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3331—Pressure; Flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3368—Temperature
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers

Definitions

  • This application is in the field of intelligent medical care, and specifically relates to a skin drug delivery control method and device.
  • Drug therapy is a common means of treatment.
  • the absorption effect of drugs has a great influence on the effect of treatment.
  • drug treatment is carried out through oral administration, injection, patching, fumigation and other administration methods.
  • the above-mentioned administration Among the methods, the invasive drug delivery process has higher requirements for drugs, while the non-invasive drug delivery process has inaccurate drug administration, resulting in a low drug absorption rate.
  • the main purpose of this application is to provide a skin drug delivery control method and device to solve the technical problem of inaccurate drug delivery in the prior art drug delivery process, improve the drug delivery accuracy, and thereby improve the drug delivery process. Efficiency technical effects.
  • the first aspect of this application proposes a skin drug delivery control method, which is used to control the drug to be administered in a non-invasive way through the skin to achieve drug delivery treatment of internal diseases and external treatment. It is applied to settings In a drug delivery device with a drug delivery unit, the drug delivery control method includes:
  • characteristic data of the type of medication to be administered is characteristic data used to represent the condition to be treated with medication
  • the drug administration characteristic data is determined according to the drug administration disease type characteristic data, wherein the drug administration characteristic data includes drug administration meridian position characteristic data and drug administration data, so that the drug administration through the drug administration meridian position corresponds to the disease to be treated. meridians between locations; and
  • the drug delivery unit is controlled according to the drug delivery characteristic data to provide power for drug penetration through the skin for skin drug delivery at the location of the drug delivery meridian.
  • determining the dosing characteristic data based on the dosing disease characteristic data includes:
  • the drug administration meridian characteristic data is used to represent the meridian data corresponding to the treatment of the disease to be administered;
  • the medication data is data used to represent the drug to be administered
  • the administration meridian location feature data and the administration drug data are subjected to administration feature generation processing to obtain the administration feature data.
  • identifying the characteristic data of the medication type and obtaining the characteristic data of the medication meridian includes:
  • MRI image of the disease type is an MRI image used to represent the disease to be treated with medication
  • the MRI image of the disease type is subjected to a meridian feature extraction process based on image segmentation and recognition to obtain the drug administration meridian feature data.
  • controlling the power of the drug delivery unit to provide drug penetration through the skin for skin drug delivery at the drug delivery meridian location based on the drug delivery characteristic data includes:
  • Identify the drug administration characteristic data to obtain the drug administration meridian location characteristic data and the drug administration data;
  • the medication unit At the location of the medication meridian corresponding to the location characteristic data of the medication meridian, the medication unit carries the medication corresponding to the medication data, and controls the connection between the medication unit and the skin according to the medication control characteristic data. Immobilizes and provides the driving force for drug penetration through the skin for dermal delivery.
  • controlling the drug delivery unit to be fixed to the skin and providing power for drug penetration through the skin for skin drug delivery based on the drug delivery control characteristic data includes:
  • Drug administration control parameters for skin drug administration are determined according to the drug administration control characteristic data, wherein the control parameters include a first control parameter and a second control parameter, and the first control parameter and the second control parameter are One of the control parameters is a pressure control parameter, and the other of the first control parameter and the second control parameter is a temperature control parameter; and
  • the pressure difference for drug administration through the skin is controlled by the pressure control parameter and the temperature control parameter, and the pressure difference is the pressure difference for drug administration through the skin.
  • the drug administration control method is applied to a drug administration device provided with an auxiliary drug administration unit and a direct drug administration unit, and the drug administration control method includes:
  • the auxiliary drug delivery unit Control the auxiliary drug delivery unit to generate a first pressure according to the first pressure control parameter, the first pressure is used to fix the drug delivery device to the skin and form a sealed drug delivery area;
  • the direct drug administration unit is controlled to generate a drug administration temperature according to the temperature control parameter, and the drug administration temperature, the first pressure and the second pressure form the pressure for skin drug administration in the closed drug administration area. Difference.
  • the administration temperature, the first pressure and the second pressure forming a pressure difference for the skin administration in the closed administration area include:
  • drug administration pressure difference data is data used to represent the pressure difference in the sealed drug administration area
  • an updated pressure control parameter is generated, wherein the updated first pressure data and the updated second pressure data are determined according to the updated pressure control parameter until the drug administration pressure difference data meets the preset drug administration pressure difference range.
  • the drug delivery device includes a first drug delivery unit and a second drug delivery unit, and the drug delivery unit is controlled according to the drug delivery characteristic data to provide drug penetration at the drug meridian location.
  • Motivations for transdermal delivery of drugs include:
  • the drug administration characteristic data is identified to obtain first drug administration characteristic data and second drug administration characteristic data, wherein the first drug administration characteristic data is the drug administration characteristic data used to control the first drug administration unit to perform skin drug administration.
  • Drug characteristic data the second drug administration characteristic data is used to control the second drug administration unit to perform skin drug administration. dosing characteristics data;
  • Control the first drug delivery unit to provide power for drug penetration through the skin for skin drug delivery at the first drug delivery meridian position according to the first drug delivery characteristic data
  • the second drug administration unit is controlled according to the second drug administration characteristic data to provide power for drug penetration through the skin for skin drug administration at the second drug administration meridian position.
  • T is the control parameter of the temperature unit in the drug delivery unit
  • drug administration is determined based on the control parameters of the first pressure unit, the control parameters of the second pressure unit and the control parameters of the temperature unit in the drug delivery unit
  • Pressure difference is the pressure difference that penetrates the skin for drug delivery.
  • a skin drug delivery control device which is used to control the drug to be administered in a non-invasive way through the skin to achieve drug delivery treatment of internal diseases and external treatment. It is applied to a device equipped with a drug delivery unit.
  • the drug delivery control device includes:
  • a disease type determination module used to determine the characteristic data of the type of medication to be administered, wherein the characteristic data of the type of medication to be administered is characteristic data used to represent the condition to be treated with medication;
  • a drug administration determination module determines drug administration characteristic data according to the drug administration disease type characteristic data, wherein the drug administration characteristic data includes drug administration meridian position characteristic data and drug administration data, so that the drug is administered through the position of the drug administration meridian. Administer the drug through the meridians corresponding to the location of the condition to be treated; and
  • a drug delivery module is controlled to control the drug delivery unit according to the drug delivery characteristic data to provide power for drug to penetrate the skin for skin drug delivery at the location of the drug delivery meridian.
  • the drug administration determination module includes:
  • the disease identification module is used to identify the characteristic data of the drug-administered disease type and obtain the characteristic data of the drug-administered meridian, wherein the characteristic data of the drug-administered meridian is used to represent the treatment of the disease to be treated. Corresponding meridian data;
  • a drug administration location determination module configured to determine the drug administration meridian position characteristic data based on the drug administration meridian characteristic data, wherein the drug administration meridian position characteristic data is data used to represent the drug administration location;
  • the drug administration determination module is used to match the drug administration data corresponding to the characteristic data of the drug administration disease in the preset drug administration database, wherein the drug administration data is used to represent the drug to be administered. data;
  • a drug administration characteristic determination module is configured to perform drug administration characteristic generation processing on the drug administration meridian location characteristic data and the drug administration drug data to obtain the drug administration characteristic data.
  • the disease identification module includes:
  • the medication meridian feature matching module is used to traverse the preset meridian medication database and determine whether there is medication meridian feature data corresponding to the medication disease characteristic data in the preset meridian medication database. If there is, obtain Characteristic data of the drug administration meridian;
  • MRI image of the disease type is an MRI image used to represent the disease to be treated with medication
  • the MRI image of the disease type is subjected to a meridian feature extraction process based on image segmentation and recognition to obtain the drug administration meridian feature data.
  • the controlled drug delivery module includes:
  • a drug administration characteristic identification module used to identify the drug administration characteristic data and obtain the drug administration meridian location characteristic data and the drug administration drug data;
  • a drug delivery control feature matching module configured to match drug delivery control feature data corresponding to the drug delivery meridian location feature data and the drug delivery drug data in a preset drug delivery database, where the drug delivery control feature data is used Data representing the dynamics that control the penetration of a drug through the skin for dermal delivery;
  • a drug administration control module is used to control the drug administration at the drug administration meridian position corresponding to the drug administration meridian position characteristic data.
  • the drug administration unit carries the drug administration drug corresponding to the drug administration drug data.
  • the drug delivery unit is fixed to the skin and provides a driving force for the drug to penetrate the skin for skin drug administration.
  • the drug delivery control module includes:
  • a control parameter determination module configured to determine drug administration control parameters for skin drug administration according to the drug administration control characteristic data, wherein the control parameters include a first control parameter and a second control parameter, and the first control parameter and one of the second control parameters is a pressure control parameter, and the other of the first control parameter and the second control parameter is a temperature control parameter; and
  • a pressure difference module configured to control the pressure difference for drug delivery through the skin through the pressure control parameter and the temperature control parameter, where the pressure difference is the pressure difference for drug delivery through the skin.
  • the drug administration control method is applied to a drug administration device provided with an auxiliary drug administration unit and a direct drug administration unit, and the drug administration control device includes:
  • a control parameter identification module used to identify the pressure control parameters to obtain first pressure control parameters and second pressure control parameters
  • a first pressure module configured to control the auxiliary drug delivery unit to generate a first pressure according to the first pressure control parameter.
  • the first pressure is used to fix the drug delivery device to the skin and form a sealed drug delivery device. area;
  • a second pressure module configured to control the direct drug administration unit to generate a second pressure according to the second pressure control parameter, the first pressure being less than the second pressure
  • a temperature control module configured to control the direct drug administration unit to generate a drug administration temperature according to the temperature control parameter
  • a pressure difference drug administration module configured to form a pressure difference for skin drug administration in the closed drug administration area based on the drug administration temperature, the first pressure and the second pressure.
  • the pressure difference drug delivery module includes:
  • a pressure difference acquisition module used to obtain drug administration pressure difference data, wherein the drug administration pressure difference data is data used to represent the pressure difference in the sealed drug administration area;
  • a pressure difference judgment module used to judge whether the drug administration pressure difference data meets the preset drug administration pressure difference range
  • the pressure difference control module if not satisfied, generates updated pressure control parameters, wherein the updated first pressure data and the updated second pressure data are determined according to the updated pressure control parameters until the drug administration pressure difference data meets the preset Dosing pressure differential range;
  • the drug administration device includes a first drug administration unit and a second drug administration unit
  • the control drug administration module includes:
  • a drug administration identification module used to identify the drug administration characteristic data to obtain first drug administration characteristic data and second drug administration characteristic data, wherein the first drug administration characteristic data is used to control the first drug administration
  • the drug delivery characteristic data is the drug delivery characteristic data used by the second drug delivery unit to perform skin drug administration
  • the second drug delivery characteristic data is the drug delivery characteristic data used to control the second drug delivery unit to perform skin drug administration
  • a first drug administration location identification module used to identify the first drug administration characteristic data and obtain the first drug administration meridian position
  • a second drug administration location identification module used to identify the second drug administration characteristic data to obtain the second drug administration meridian position
  • a first drug delivery module configured to control the first drug delivery unit to provide power for drug penetration through the skin for skin drug delivery at the first drug delivery meridian position according to the first drug delivery characteristic data
  • a second drug delivery module is configured to control the second drug delivery unit to provide power for drug penetration through the skin for skin drug delivery at the second drug delivery meridian position based on the second drug delivery characteristic data.
  • the control parameters of the first pressure unit and the second pressure unit, T is the control parameter of the temperature unit in the drug delivery unit; according to the control parameters of the first pressure unit, the control parameters of the second pressure unit and the temperature unit in the drug delivery unit
  • the control parameters determine the pressure difference for drug delivery, which is the pressure difference for drug delivery through the skin.
  • a computer-readable storage medium stores computer instructions, and the computer instructions are used to cause the computer to execute the above-mentioned skin drug delivery control method.
  • an electronic device including: at least one processor; and a memory communicatively connected to the at least one processor; wherein the memory stores information that can be used by the at least one processor.
  • a computer program is executed, and the computer program is executed by the at least one processor, so that the at least one processor executes the above-mentioned skin drug delivery control method.
  • the characteristic data of the drug type are determined, and the drug including drug is determined according to the characteristic data of the drug type.
  • the drug delivery feature data of the meridian position feature data and the drug delivery data are used to control the drug delivery unit to provide power for the drug to penetrate the skin at the location of the drug delivery meridian for skin drug delivery.
  • Figure 1 is a flow chart of a skin drug delivery control method provided by the present application.
  • Figure 2 is a flow chart of a skin drug delivery control method provided by the present application.
  • Figure 3 is a flow chart of a skin drug delivery control method provided by the present application.
  • Figure 4 is a schematic structural diagram of a skin drug delivery control device provided by the present application.
  • FIG. 5 is a schematic structural diagram of another skin drug delivery control device provided by this application.
  • connection can be a fixed connection, a detachable connection, or an integral structure; it can be a mechanical connection, or an electrical connection; it can be a direct connection, or an indirect connection through an intermediary, or two devices, components or Internal connections between components.
  • connection can be a fixed connection, a detachable connection, or an integral structure; it can be a mechanical connection, or an electrical connection; it can be a direct connection, or an indirect connection through an intermediary, or two devices, components or Internal connections between components.
  • the present application provides a skin drug delivery control method, which is used to control the drug to be administered in a non-invasive way through the skin to achieve drug delivery treatment of internal diseases and external treatment.
  • the drug delivery control method is applied to a device equipped with a drug delivery unit.
  • the drug delivery unit In the drug delivery device, during the drug delivery process, the drug delivery unit is fixed on the skin, providing the power for the drug to non-invasively penetrate the skin and enter the lesion location in the body to construct a drug delivery channel, and achieve internal and external treatment of internal diseases through skin drug delivery.
  • the drug delivery unit controls the non-invasive penetration of the drug through the skin, realizing the construction of a drug delivery channel from the skin to the liver.
  • the drug penetrates the skin to the liver through the drug delivery channel, realizing the Skin drug administration realizes the treatment of liver diseases, which are organs in the body. Skin drug administration realizes the treatment of liver diseases, achieving external treatment of internal diseases.
  • Figure 1 is a flow chart of a skin drug delivery control method provided by the present application. As shown in Figure 1, the method includes:
  • S101 Determine the characteristic data of the disease to be administered
  • the characteristic data of the type of medication to be administered is the characteristic data used to represent the condition to be treated with medication.
  • the characteristic data of the type of medication to be administered is the data obtained through human-computer interaction and used to describe the condition to be treated with medication, including data obtained based on human-computer interaction.
  • Different forms of drug-medication disease characteristic data such as medical record documents, disease images (such as CT images, etc., tongue coating images, eyeball images, etc.), voice (such as voice symptom descriptions), by obtaining different forms of drug-medication disease characteristic data, Improve the accuracy of the description of the disease to be treated with medication, so as to improve the efficiency of medication when administering medication based on the characteristic data of the disease.
  • the characteristic data of the medication type can also be evidence/symptoms, used to represent abnormalities that occur after the patient becomes ill, including data obtained through manual interaction to represent symptoms and signs, such as voice form, text form or document form. Symptoms and signs data.
  • S102 Determine the medication characteristic data based on the medication disease characteristic data
  • the drug administration characteristic data includes drug administration meridian position characteristic data and drug administration data, so that the drug is administered through the meridian between the position of the drug meridian and the position corresponding to the disease to be treated. through skin
  • the drug is administered through the meridians between the location of the administration meridians and the location corresponding to the disease to be treated, and the skin administration location and drug administration are determined based on the drug delivery characteristic data to achieve Improve dosing accuracy when administering medication.
  • Figure 2 is a flow chart of a skin drug delivery control method provided by the present application. As shown in Figure 2, the method includes:
  • the drug administration meridian characteristic data is used to represent the meridian data corresponding to the disease to be administered.
  • meridians refer to the pathways through which qi and blood circulate in the human body. Research has found that interstitial fluid circulation widely exists in the human body and forms an interstitial fluid transmission network throughout the body. The interstitial fluid transmission path of the human body is closely related to the distribution of acupuncture points.
  • the characteristic data of the drug administration meridians are the relevant meridians at the location of the disease to be treated with medication, and the TCM meridians corresponding to the tissue fluid circulation at the location of the disease to be treated with medication. For example, facial paralysis is caused by facial nerve paralysis or facial nerve injury.
  • the disease is a neurological disease.
  • the meridian corresponding to facial paralysis corresponds to the Du meridian.
  • the Du meridian runs in the middle of the back. Its meridian intersects with the three yang meridians of the hands and feet and the Yangwei meridians many times. It can govern the yang meridians of the body.
  • the Du meridian runs in In the spine, it goes up into the brain.
  • the disease type characteristic data is identified to obtain the disease type MRI image, where the disease type MRI image is an MRI image used to represent the disease to be treated with medication; the disease type MRI image is subjected to meridian feature extraction processing based on image segmentation and recognition, and the disease type MRI image is obtained. Characteristic data of medicinal meridians.
  • the default meridian drug administration database is set with a mapping relationship between diseases and drug administration meridians.
  • the same disease can correspond to a single meridian, and the same disease can also correspond to multiple meridians.
  • liver ascites can pass through the Taiyang Bladder Meridian.
  • Carry out drug administration; lung diseases correspond to the lung meridian, and the drug treatment of lung diseases can be carried out through the upstream or downstream meridian of the lung meridian.
  • the meridian feature data is extracted by acquiring MRI images of the disease to be treated, and the medication meridian feature data is obtained.
  • the meridian feature extraction process based on image segmentation and recognition is performed on the MRI image of the disease type, including: image segmentation and recognition of the MRI image of the disease type, and the location of the lesion in the MRI image and the tissue fluid circulation data corresponding to the lesion are obtained. According to the tissue fluid circulation data and the twelve The meridians are matched with the meridians of the eight extra meridians to obtain the characteristic data of the drug-administered meridians.
  • S202 Determine the location characteristic data of the drug administration meridian based on the drug administration meridian characteristic data
  • the drug administration meridian position feature data is data used to represent the drug administration location.
  • the drug administration meridian position feature data is used to describe the position data of the acupuncture points corresponding to the drug administration position. According to the mapping relationship between acupoints and meridians, according to the drug administration meridian characteristics
  • the data and the characteristic data of drug delivery diseases can be used to determine the acupoint locations for skin drug delivery. Since the meridian corresponding to the disease to be treated can be a single meridian or multiple meridians, the characteristic data of the medication meridian is identified.
  • the treatment strategy determines the drug administration acupoint corresponding to a single meridian. For example, for example, liver ascites can be treated with medication through the Taiyang Bladder Meridian. Based on the multiple acupoints corresponding to the Taiyang Bladder Meridian and the treatment strategy for diuretic treatment of liver ascites, the treatment strategy is determined. Drug therapy is given at the acupoints of the double liver and kidney acupoints belonging to the Taiyang Bladder Meridian.
  • the drug administration acupoints are determined based on the upstream and downstream relationships and intersection relationships between the multiple meridians and combined with the treatment strategy of the disease to be treated.
  • lung disease, Administration and treatment can be carried out through the lung meridian, the upstream meridian and the downstream meridian of the lung.
  • the lung meridian, the upstream meridian of the lung meridian and the downstream meridian of the lung meridian, as well as the treatment strategy of the lung disease it is determined that the location is located in the lung meridian and the upstream of the lung meridian.
  • Administration and treatment are performed at multiple acupoints on the downstream meridians of the meridian and lung meridian.
  • the location of the acupoints for skin drug administration is determined through the drug administration meridians to improve the accuracy of drug administration.
  • the drug data to be administered is data used to represent the drug to be administered.
  • the drug data to be administered is determined based on the characteristic data of the disease to be administered.
  • S204 Perform drug administration feature generation processing on the drug administration meridian location feature data and the drug administration data to obtain drug administration feature data.
  • S103 Control the drug delivery unit to provide power for the drug to penetrate the skin for skin drug delivery at the drug delivery meridians according to the drug delivery characteristic data.
  • Figure 3 is a flow chart of a skin drug delivery control method provided by the present application. As shown in Figure 3, the method includes:
  • S301 Identify the drug administration characteristic data and obtain the drug administration meridian location characteristic data and drug administration data;
  • the administered drug data also includes drug feature data.
  • the drug feature data is used to represent the administered drug.
  • Characteristic data including data used to represent drug components and drug structure, for example, the components of the drug to be administered can be single-component or multi-component drugs, and the structure of the drug to be administered can be solid drugs, liquids Medication or gas pills.
  • S302 Match the drug delivery control feature data corresponding to the drug delivery meridian location feature data and the drug delivery data in the preset drug delivery database;
  • the drug administration control characteristic data is data representing the power to control the penetration of the drug through the skin for skin drug administration.
  • the drug administration meridian location feature data is used to represent the acupoint locations for skin drug administration. Due to the differences in the skin at the drug administration location, the corresponding acupoints, and the corresponding lesion locations corresponding to the location drug administration meridian location feature data, matching and drug administration meridians
  • the location drug delivery control feature data corresponding to the location feature data is matched with the drug delivery control feature data corresponding to the drug delivery control data, and the above drug delivery control feature data is determined based on the location drug delivery control feature data and the drug delivery control feature data.
  • the drug administration control characteristic data is used to control the parameters of the drug administration unit during the drug administration process, including drug administration temperature and drug administration pressure, so as to form a drug penetrating skin for skin drug administration based on the drug administration temperature and drug administration pressure. Pressure difference.
  • the medication unit At the location of the medication meridian corresponding to the location characteristic data of the medication meridian, the medication unit carries the medication corresponding to the medication data, and controls the medication unit to be fixed to the skin according to the medication control characteristic data and provides the medication to penetrate the skin. Motivation for dermal drug delivery.
  • a skin drug delivery control method which method includes:
  • Drug administration control parameters for skin drug administration are determined according to the drug administration control characteristic data, wherein the control parameters include a first control parameter and a second control parameter, and one of the first control parameter and the second control parameter is pressure.
  • Control parameter, the other parameter among the first control parameter and the second control parameter is a temperature control parameter; the pressure difference for skin drug administration is controlled through the pressure control parameter and the temperature control parameter, and the pressure difference is the pressure difference for drug administration through the skin. Pressure difference.
  • the drug administration control method is applied to a drug administration device provided with an auxiliary drug administration unit and a direct drug administration unit.
  • the drug administration control method includes: identifying the pressure control parameters, and obtaining the first Pressure control parameters and second pressure control parameters; according to the first pressure control parameter, the auxiliary drug administration unit is controlled to generate a first pressure, and the first pressure is used to fix the drug administration device to the skin and form a sealed drug administration area; according to the second
  • the pressure control parameter controls the direct drug administration unit to generate a second pressure, and the first pressure is less than the second pressure; and the temperature control parameter controls the direct drug administration unit to generate a drug administration temperature, and the direct drug administration unit generates a drug administration temperature according to the drug administration temperature, the first pressure and the third pressure.
  • Pressure forms the pressure of skin drug administration in the closed drug administration area Difference.
  • the administration temperature, the first pressure and the second pressure forming a pressure difference for skin administration in a closed administration area include: obtaining administration pressure difference data, wherein: administration pressure difference data is data used to represent the pressure difference in a closed dosing area; it is judged whether the dosing pressure difference data meets the preset dosing pressure difference range. If not, an updated pressure control parameter is generated, in which the updated pressure control parameter is determined according to the updated pressure control parameter. The first pressure data and the second pressure data are updated until the drug administration pressure difference data meets the preset drug administration pressure difference range; and if satisfied, drug administration is performed in a closed drug administration area.
  • the administration temperature, the first pressure and the second pressure forming a pressure difference for skin administration in a closed administration area include: obtaining administration pressure difference data, wherein: administration pressure difference data is data used to represent the pressure difference in a closed area; determine whether the drug administration pressure difference data meets the preset drug administration pressure difference range; if not, generate updated temperature control parameters, in which the updated temperature is determined according to the temperature control parameters until The drug administration pressure difference meets the preset drug administration pressure difference range; if so, drug administration is performed in a closed drug administration area.
  • the drug drug delivery characteristic data is determined according to the characteristics of the disease, and different drug administration locations and drugs are determined based on the drug drug administration characteristic data.
  • the skin drug administration scheme at different drug administration locations including drug administration location, drug administration, and drug administration control parameters
  • va and vb are the first pressure unit and the second pressure unit in the drug administration unit respectively.
  • the control parameters of T are the control parameters of the temperature unit in the drug delivery unit.
  • the medication unit includes a direct medication unit and an auxiliary medication unit.
  • the direct medication unit is provided with a direct medication pressure unit and a temperature unit, and the auxiliary medication unit is configured with an auxiliary medication unit.
  • Medicine pressure unit is used to control the auxiliary drug administration unit to generate the first pressure to achieve fixation of the drug administration unit and the skin and form a closed drug administration area.
  • the direct drug administration pressure unit is used to control the direct drug administration unit to generate the second pressure.
  • the temperature unit controls the direct drug administration unit to generate a drug administration temperature, and controls the pressure difference generated in the closed drug administration area formed by the drug drug administration unit and the skin through the first pressure, the second pressure and the drug administration temperature to control the penetration of the drug through the skin for drug administration.
  • Controlling the pressure difference of skin drug delivery through pressure control parameters and temperature control parameters includes: determining a drug delivery control model corresponding to the above drug delivery control characteristic data according to the drug delivery control characteristic data. Detect the contact between the drug delivery device and the skin, control the drug delivery device to change the pressure and temperature according to the above drug delivery control model, detect the pressure difference in the drug delivery area through the pressure difference detection element provided in the drug delivery device, and determine the pressure Whether the difference data meets the drug delivery pressure difference range corresponding to the above drug delivery control model. If not, the drug delivery control model generates pressure adjustment parameters and temperature adjustment parameters based on the currently detected pressure difference data, and the pressure module performs pressure adjustment based on the pressure adjustment parameters.
  • the temperature module adjusts the temperature according to the temperature adjustment parameters, monitors the pressure difference during the drug administration process, and performs feedback adjustment based on the monitored pressure difference data according to the drug administration control model to control the temperature in the drug administration area
  • the difference data is within the preset drug delivery pressure difference range, and skin drug delivery is performed.
  • feedback control is performed during the drug administration process.
  • the temperature and temperature can be controlled during the drug administration process.
  • the control of pressure further realizes the control of drug delivery pressure difference.
  • the pressure difference forms the driving force for the drug to penetrate the skin and act on the disease location, thereby improving the drug delivery efficiency.
  • a method for controlling skin drug administration includes: identifying drug administration characteristic data to obtain first drug administration characteristic data and second drug administration characteristic data, wherein , the first drug administration characteristic data is drug administration characteristic data used to control the first drug administration unit to perform skin drug administration, and the second drug administration characteristic data is used to control the second drug administration unit to perform skin drug administration.
  • the drugs to be administered are drugs for activating collaterals and removing blood stasis.
  • the double kidney acupoints belong to the bladder meridian of Foot and Taiyang. , the kidneys can regulate the body's water metabolism, thereby maintaining the normal operation of the body.
  • the first medication unit administers medication at the double liver acupoints
  • the second medication unit administers medication at the double kidney acupoints.
  • the first and second medication units are controlled at the positions of the double liver acupoints and the double kidney acupoints respectively.
  • the drugs to be administered are drugs for activating collaterals and removing blood stasis.
  • Dazhui is the meridian of the Governor Vessel and the three yang meridians of the hands and feet.
  • the Jiaohui point which leads to the brain, has the function of governing all Yangs, and has the effects of relieving the external yang, clearing the brain and calming the mind;
  • the Lingtai point which belongs to the Du meridian, has the effect of replenishing Qi and tonifying Yang.
  • the first drug administration unit administers drugs at Dazhui point
  • the second drug administration unit administers drugs at Lingtai acupoint.
  • the first and second drug administration units are controlled to provide drug administration at the positions respectively located at Dazhui acupoint and Lingtai acupoint.
  • the power to penetrate the skin is controlled by controlling the pressure and temperature parameters in the first and second drug delivery units to control the pressure difference in the drug delivery area.
  • a drug delivery device for skin drug delivery is provided.
  • One drug delivery unit or multiple drug delivery units may be provided in the drug delivery device; the drug delivery unit
  • each administration unit can be controlled individually or as a whole, and the administration pressure difference in the administration unit can be controlled, including controlling the time, pressure, temperature, etc. of administration.
  • the administration unit is communicated with the cloud platform. , to achieve information interaction with the cloud platform.
  • FIG 4 is a schematic structural diagram of a skin drug delivery control device provided by this application. As shown in Figure 4, the device includes:
  • the disease type determination module 41 is used to determine the characteristic data of the disease type to be administered, where the characteristic data of the disease type to be administered is the characteristic data used to represent the disease to be treated with medication;
  • the drug administration determination module 42 determines drug administration characteristic data according to the drug administration disease type characteristic data, wherein the drug administration characteristic data includes drug administration meridian position characteristic data and drug administration data, so that the drug administration through the drug administration meridian position is consistent with the location of the drug to be treated. Drugs are administered through the meridians between the corresponding locations of the disease;
  • the drug delivery module 43 is controlled to control the drug delivery unit to provide power for the drug to penetrate the skin for skin drug delivery at the location of the drug delivery meridian based on the drug delivery characteristic data.
  • FIG. 5 is a schematic structural diagram of another skin drug delivery control device provided by this application. As shown in Figure 5, the device includes:
  • the disease type identification module 51 is used to identify the characteristic data of the medication type of disease and obtain the characteristic data of the medication meridians, where the characteristic data of the medication meridians are the meridian data used to represent the corresponding meridian data for treating the disease to be treated;
  • the drug administration location determination module 52 is used to determine the drug administration meridian position characteristic data based on the drug administration meridian characteristic data, where the drug administration meridian position characteristic data is data used to represent the drug administration location;
  • the medication determination module 53 is used to match the number of medication disease characteristics in the preset medication database. According to the corresponding drug administration data, wherein the drug administration data is data used to represent the drug to be administered; and
  • the drug administration characteristic determination module 54 is used to perform drug administration characteristic generation processing on the drug administration meridian location characteristic data and the drug administration drug data to obtain drug administration characteristic data.
  • the drug is controlled to be administered in a non-invasive way through the skin to achieve drug treatment of internal diseases and external treatment, and the characteristic data of the drug type are determined.
  • the data determines the drug delivery feature data including the drug delivery meridian position feature data and the drug delivery data.
  • the drug delivery unit is controlled to provide a driving force for the drug to penetrate the skin at the drug delivery meridian position for skin drug delivery. Determining the administration location and administration drug for skin administration for treating diseases solves the problem of inaccurate administration process in the existing technology and achieves the technical effect of improving administration accuracy and administration efficiency.
  • each unit or step of the above-mentioned application can be implemented by a general computing device, and they can be concentrated on a single computing device, or distributed across a network composed of multiple computing devices. , optionally, they can be implemented with program codes executable by a computing device, so that they can be stored in a storage device and executed by the computing device, or they can be separately made into individual integrated circuit modules, or they can be Multiple modules or steps are made into a single integrated circuit module. As such, the application is not limited to any specific combination of hardware and software.

Abstract

一种皮肤给药控制方法和装置，用于控制药物以无创穿透皮肤的方式进行给药以实现内病外治的给药治疗。该方法包括：S101：确定给药病种特征数据；S102：根据所述给药病种特征数据确定包括给药经脉位置特征数据和给药药物数据的给药特征数据，以便给药药物通过给药经脉位置与待治疗病症对应位置之间的经脉进行给药；S103：根据给药特征数据控制给药单元在给药经脉位置处提供药物穿透皮肤进行皮肤给药的动力。该方法和装置通过根据待治疗病症确定进行皮肤给药的给药位置和给药药物，解决了现有技术中给药过程不精准的问题，实现了提高给药精准性和给药效率的技术效果。

Description

皮肤给药控制方法和装置
本申请要求2022年7月28日提交至中国知识产权局的，申请号为202210895737.9，名称为“皮肤给药控制方法和装置”的中国发明专利申请的优先权，其全部公开内容结合于此作为参考。
技术领域
本申请智能医疗领域，具体而言，涉及一种皮肤给药控制方法和装置。
背景技术
药物治疗是进行治疗的一种常用手段，药物的吸收效果对治疗的效果影响较大，现有技术中，通过包括口服、注射、贴敷及熏蒸等给药方式进行给药治疗，上述给药方式中有创给药过程对药物要求较高，无创给药过程药物存在给药不精准导致药物吸收率较低。
因此，现有技术中给药过程存在给药不精准的问题。
发明内容
本申请的主要目的在于提供一种皮肤给药控制方法和装置，以解决现有技术给药过程存在给药不精准的技术问题，提高给药精准性，进而实现了提高给药过程中给药效率的技术效果。
为了实现上述目的，本申请的第一方面，提出了一种皮肤给药控制方法，用于控制药物以无创穿透皮肤的方式进行给药以实现内病外治的给药治疗，应用于设置有给药单元的给药装置中，所述给药控制方法包括：
确定给药病种特征数据，其中，所述给药病种特征数据为用于表示待给药治疗病症的特征数据；
根据所述给药病种特征数据确定给药特征数据，其中，所述给药特征数据包括给药经脉位置特征数据和给药药物数据，以便给药药物通过给药经脉位置与待治疗病症对应位置之间的经脉进行给药；以及
根据所述给药特征数据控制所述给药单元在给药经脉位置提供药物穿透皮肤进行皮肤给药的动力。
在本申请的一些实施例中，根据所述给药病种特征数据确定给药特征数据包括：
对所述给药病种特征数据进行识别，得到给药经脉特征数据，其中，所述 给药经脉特征数据为用于表示治疗所述待给药治疗病症对应的经脉数据；
根据所述给药经脉特征数据确定给药经脉位置特征数据，其中，所述给药经脉位置特征数据为用于表示给药位置的数据；
在预设给药数据库中匹配与所述给药病种特征数据对应的所述给药药物数据，其中，所述给药药物数据为用于表示待给药药物的数据；以及
对所述给药经脉位置特征数据和所述给药药物数据进行给药特征生成处理，得到所述给药特征数据。
在本申请的一些实施例中，对所述给药病种特征数据进行识别，得到给药经脉特征数据包括：
遍历预设经脉给药数据库，判断所述预设经脉给药数据库中是否存在与所述给药病种特征数据对应的给药经脉特征数据，如果存在，得到所述给药经脉特征数据；
如果不存在，对所述给药病种特征数据进行识别，得到病种核磁图像，其中，所述病种核磁图像为用于表示待给药治疗病症的核磁图像；以及
对所述病种核磁图像进行基于图像分割识别的经脉特征提取处理，得到所述给药经脉特征数据。
在本申请的一些实施例中，根据所述给药特征数据控制所述给药单元在给药经脉位置提供药物穿透皮肤进行皮肤给药的动力包括：
对所述给药特征数据进行识别，得到所述给药经脉位置特征数据和所述给药药物数据；
在预设给药数据库中匹配与所述给药经脉位置特征数据和所述给药药物数据对应的给药控制特征数据，所述给药控制特征数据为用于表示控制药物穿透皮肤进行皮肤给药的动力的数据；以及
在所述给药经脉位置特征数据对应的给药经脉位置，所述给药单元承载所述给药药物数据对应的给药药物，根据所述给药控制特征数据控制所述给药单元与皮肤固定并提供药物穿透皮肤进行皮肤给药的动力。
在本申请的一些实施例中，根据所述给药控制特征数据控制所述给药单元与皮肤固定并提供药物穿透皮肤进行皮肤给药的动力包括：
根据所述给药控制特征数据确定用于皮肤给药的给药控制参数，其中，所述控制参数包括第一控制参数和第二控制参数，所述第一控制参数和所述第二 控制参数中的一个参数为压力控制参数，所述第一控制参数和所述第二控制参数中的另一个参数为温度控制参数；以及
通过所述压力控制参数和所述温度控制参数对皮肤给药的压力差进行控制，所述压力差为穿透所述皮肤进行给药的压力差。
在本申请的一些实施例中，所述给药控制方法应用于设置有辅助给药单元和直接给药单元的给药装置中，所述给药控制方法包括：
对所述压力控制参数进行识别，得到第一压力控制参数和第二压力控制参数；
根据所述第一压力控制参数控制所述辅助给药单元生成第一压力，所述第一压力用于将所述给药装置固定于所述皮肤且形成密闭给药区域；
根据所述第二压力控制参数控制所述直接给药单元生成第二压力，所述第一压力小于所述第二压力；以及
根据所述温度控制参数控制所述直接给药单元生成给药温度，所述给药温度、所述第一压力和所述第二压力在所述密闭给药区域形成所述皮肤给药的压力差。
在本申请的一些实施例中，所述给药温度、所述第一压力和所述第二压力在所述密闭给药区域形成所述皮肤给药的压力差包括：
获取给药压力差数据，其中，所述给药压力差数据为用于表示所述密闭给药区域内压力差的数据；
判断所述给药压力差数据是否满足预设给药压力差范围，
如果不满足，生成更新压力控制参数，其中，根据所述更新压力控制参数确定更新第一压力数据和更新第二压力数据，直至所述给药压力差数据满足所述预设给药压力差范围；以及
如果满足，在所述密闭给药区域内进行给药。
在本申请的一些可选实施例中，所述给药装置包括第一给药单元和第二给药单元，根据所述给药特征数据控制所述给药单元在给药经脉位置提供药物穿透皮肤进行皮肤给药的动力包括：
对所述给药特征数据进行识别，得到第一给药特征数据和第二给药特征数据，其中，所述第一给药特征数据为用于控制第一给药单元进行皮肤给药的给药特征数据，所述第二给药特征数据为用于控制第二给药单元进行皮肤给药的 给药特征数据；
对所述第一给药特征数据进行识别，得到第一给药经脉位置；
对所述第二给药特征数据进行识别，得到第二给药经脉位置；
根据所述第一给药特征数据控制所述第一给药单元在所述第一给药经脉位置提供药物穿透皮肤进行皮肤给药的动力；以及
根据所述第二给药特征数据控制所述第二给药单元在所述第二给药经脉位置提供药物穿透皮肤进行皮肤给药的动力。
在本申请的一些可选实施例中，根据所述给药病种特征数据确定给药经脉位置特征数据和给药药物数据的表达式为：S＝c(c1，c2，…cn)，ci＝f(va，vb，T)，其中，S表示所述给药病种特征数据对应的皮肤给药方案数据，ci为所述给药位置特征数据对应给药位置的皮肤给药方案数据，其中，所述给药位置特征数据对应给药位置的皮肤给药方案数据包括给药位置数据、给药药物数据和给药控制参数数据，va和vb分别为给药单元中的第一压力单元和第二压力单元的控制参数，T为给药单元中温度单元的控制参数；根据给药单元中第一压力单元的控制参数、第二压力单元的控制参数和温度单元的控制参数确定给药压力差，压力差为穿透皮肤进行给药的压力差。
根据本申请的第二方面，提供一种皮肤给药控制装置，用于控制药物以无创穿透皮肤的方式进行给药以实现内病外治的给药治疗，应用于设置有给药单元的给药装置中，所述给药控制装置包括：
病种确定模块，用于确定给药病种特征数据，其中，所述给药病种特征数据为用于表示待给药治疗病症的特征数据；
给药确定模块，根据所述给药病种特征数据确定给药特征数据，其中，所述给药特征数据包括给药经脉位置特征数据和给药药物数据，以便给药药物通过给药经脉位置与待治疗病症对应位置之间的经脉进行给药；以及
控制给药模块，根据所述给药特征数据控制所述给药单元在给药经脉位置提供药物穿透皮肤进行皮肤给药的动力。
在本申请的一些可选实施例中，根据权利要求1所述的给药控制装置，给药确定模块包括：
病种识别模块，用于对所述给药病种特征数据进行识别，得到给药经脉特征数据，其中，所述给药经脉特征数据为用于表示治疗所述待给药治疗病症对 应的经脉数据；
给药位置确定模块，用于根据所述给药经脉特征数据确定给药经脉位置特征数据，其中，所述给药经脉位置特征数据为用于表示给药位置的数据；
给药药物确定模块，用于在预设给药数据库中匹配与所述给药病种特征数据对应的所述给药药物数据，其中，所述给药药物数据为用于表示待给药药物的数据；以及
给药特征确定模块，用于对所述给药经脉位置特征数据和所述给药药物数据进行给药特征生成处理，得到所述给药特征数据。
在本申请的一些可选实施例中，病种识别模块包括：
给药经脉特征匹配模块，用于遍历预设经脉给药数据库，判断所述预设经脉给药数据库中是否存在与所述给药病种特征数据对应的给药经脉特征数据，如果存在，得到所述给药经脉特征数据；
如果不存在，对所述给药病种特征数据进行识别，得到病种核磁图像，其中，所述病种核磁图像为用于表示待给药治疗病症的核磁图像；以及
对所述病种核磁图像进行基于图像分割识别的经脉特征提取处理，得到所述给药经脉特征数据。
在本申请的一些可选实施例中，控制给药模块包括：
给药特征识别模块，用于对所述给药特征数据进行识别，得到所述给药经脉位置特征数据和所述给药药物数据；
给药控制特征匹配模块，用于在预设给药数据库中匹配与所述给药经脉位置特征数据和所述给药药物数据对应的给药控制特征数据，所述给药控制特征数据为用于表示控制药物穿透皮肤进行皮肤给药的动力的数据；以及
给药控制模块，用于在所述给药经脉位置特征数据对应的给药经脉位置，所述给药单元承载所述给药药物数据对应的给药药物，根据所述给药控制特征数据控制所述给药单元与皮肤固定并提供药物穿透皮肤进行皮肤给药的动力。
在本申请的一些可选实施例中，给药控制模块包括：
控制参数确定模块，用于根据所述给药控制特征数据确定用于皮肤给药的给药控制参数，其中，所述控制参数包括第一控制参数和第二控制参数，所述第一控制参数和所述第二控制参数中的一个参数为压力控制参数，所述第一控制参数和所述第二控制参数中的另一个参数为温度控制参数；以及
压力差模块，用于通过所述压力控制参数和所述温度控制参数对皮肤给药的压力差进行控制，所述压力差为穿透所述皮肤进行给药的压力差。
在本申请的一些可选实施例中，所述给药控制方法应用于设置有辅助给药单元和直接给药单元的给药装置中，所述给药控制装置包括：
控制参数识别模块，用于对所述压力控制参数进行识别，得到第一压力控制参数和第二压力控制参数；
第一压力模块，用于根据所述第一压力控制参数控制所述辅助给药单元生成第一压力，所述第一压力用于将所述给药装置固定于所述皮肤且形成密闭给药区域；
第二压力模块，用于根据所述第二压力控制参数控制所述直接给药单元生成第二压力，所述第一压力小于所述第二压力；以及
温度控制模块，用于根据所述温度控制参数控制所述直接给药单元生成给药温度；
压力差给药模块，用于根据所述给药温度、所述第一压力和所述第二压力在所述密闭给药区域形成所述皮肤给药的压力差。
在本申请的一些可选实施例中，压力差给药模块包括：
压力差获取模块，用于获取给药压力差数据，其中，所述给药压力差数据为用于表示所述密闭给药区域内压力差的数据；
压力差判断模块，用于判断所述给药压力差数据是否满足预设给药压力差范围，
压力差控制模块，如果不满足，生成更新压力控制参数，其中，根据所述更新压力控制参数确定更新第一压力数据和更新第二压力数据，直至所述给药压力差数据满足所述预设给药压力差范围；以及
如果满足，在所述密闭给药区域内进行给药。
在本申请的一些可选实施例中，所述给药装置包括第一给药单元和第二给药单元，控制给药模块包括：
给药识别模块，用于对所述给药特征数据进行识别，得到第一给药特征数据和第二给药特征数据，其中，所述第一给药特征数据为用于控制第一给药单元进行皮肤给药的给药特征数据，所述第二给药特征数据为用于控制第二给药单元进行皮肤给药的给药特征数据；
第一给药位置识别模块，用于对所述第一给药特征数据进行识别，得到第一给药经脉位置；
第二给药位置识别模块，用于对所述第二给药特征数据进行识别，得到第二给药经脉位置；
第一给药模块，用于根据所述第一给药特征数据控制所述第一给药单元在所述第一给药经脉位置提供药物穿透皮肤进行皮肤给药的动力；以及
第二给药模块，用于根据所述第二给药特征数据控制所述第二给药单元在所述第二给药经脉位置提供药物穿透皮肤进行皮肤给药的动力。
在本申请的一些可选实施例中，给药确定模块，根据所述给药病种特征数据确定给药经脉位置特征数据和给药药物数据的表达式为：S＝c(c1，c2，…cn)，ci＝f(va，vb，T)，其中，S表示所述给药病种特征数据对应的皮肤给药方案数据，ci为所述给药位置特征数据对应给药位置的皮肤给药方案数据，其中，所述给药位置特征数据对应给药位置的皮肤给药方案数据包括给药位置数据、给药药物数据和给药控制参数数据，va和vb分别为给药单元中的第一压力单元和第二压力单元的控制参数，T为给药单元中温度单元的控制参数；根据给药单元中第一压力单元的控制参数、第二压力单元的控制参数和温度单元的控制参数确定给药压力差，压力差为穿透皮肤进行给药的压力差。
根据本申请的第三方面，提供了一种计算机可读存储介质，所述计算机可读存储介质存储有计算机指令，所述计算机指令用于使所述计算机执行上述的皮肤给药控制方法。
根据本申请的第四方面，提供了一种电子设备，包括：至少一个处理器；以及与所述至少一个处理器通信连接的存储器；其中，所述存储器存储有可被所述至少一个处理器执行的计算机程序，所述计算机程序被所述至少一个处理器执行，以使所述至少一个处理器执行上述的皮肤给药控制方法。
本申请的实施例提供的技术方案可以包括以下有益效果：
在本申请中，通过控制药物以无创穿透皮肤的方式进行给药以实现内病外治的给药治疗，确定给药病种特征数据，根据所述给药病种特征数据确定包括给药经脉位置特征数据和给药药物数据的给药特征数据，根据给药特征数据控制给药单元在给药经脉位置处提供药物穿透皮肤进行皮肤给药的动力，通过根据待治疗病症确定进行皮肤给药的给药位置和给药药物，解决了现有技术中给 药过程不精准的问题，实现了提高给药精准性和给药效率的技术效果。
附图说明
构成本申请的一部分的附图用来提供对本申请的进一步理解，使得本申请的其它特征、目的和优点变得更明显。本申请的示意性实施例附图及其说明用于解释本申请，并不构成对本申请的不当限定。在附图中：
图1为本申请提供的一种皮肤给药控制方法的流程图；
图2为本申请提供的一种皮肤给药控制方法的流程图；
图3为本申请提供的一种皮肤给药控制方法的流程图；
图4为本申请提供的一种皮肤给药控制装置的结构示意图；
图5为本申请提供的另一种皮肤给药控制装置的结构示意图。
具体实施方式
为了使本技术领域的人员更好地理解本申请方案，下面将结合本申请实施例中的附图，对本申请实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本申请一部分的实施例，而不是全部的实施例。基于本申请中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都应当属于本申请保护的范围。
需要说明的是，本申请的说明书和权利要求书及上述附图中的术语“第一”、“第二”等是用于区别类似的对象，而不必用于描述特定的顺序或先后次序。应该理解这样使用的数据在适当情况下可以互换，以便这里描述的本申请的实施例。此外，术语“包括”和“具有”以及他们的任何变形，意图在于覆盖不排他的包含，例如，包含了一系列步骤或单元的过程、方法、系统、产品或设备不必限于清楚地列出的那些步骤或单元，而是可包括没有清楚地列出的或对于这些过程、方法、产品或设备固有的其它步骤或单元。
在本申请中，术语“上”、“下”、“左”、“右”、“前”、“后”、“顶”、“底”、“内”、“外”、“中”、“竖直”、“水平”、“横向”、“纵向”等指示的方位或位置关系为基于附图所示的方位或位置关系。这些术语主要是为了更好地描述本申请及其实施例，并非用于限定所指示的装置、元件或组成部分必须具有特定方位，或以特定方位进行构造和操作。
并且，上述部分术语除了可以用于表示方位或位置关系以外，还可能用于表示其他含义，例如术语“上”在某些情况下也可能用于表示某种依附关系或 连接关系。对于本领域普通技术人员而言，可以根据具体情况理解这些术语在本申请中的具体含义。
此外，术语“安装”、“设置”、“设有”、“连接”、“相连”、“套接”应做广义理解。例如，“连接”可以是固定连接，可拆卸连接，或整体式构造；可以是机械连接，或电连接；可以是直接相连，或者是通过中间媒介间接相连，又或者是两个装置、元件或组成部分之间内部的连通。对于本领域普通技术人员而言，可以根据具体情况理解上述术语在本申请中的具体含义。
本申请提供了一种皮肤给药控制方法，用于控制药物以无创穿透皮肤的方式进行给药以实现内病外治的给药治疗，该给药控制方法应用于设置有给药单元的给药装置中，在给药过程中，给药单元固定于皮肤，提供药物无创穿透皮肤进入体内病灶位置处的动力以实现给药通道的构筑，实现通过皮肤给药实现内病外治。举例说明，如，对于肝部疾病，通过给药单元控制药物无创穿透皮肤，实现了构建从皮肤至肝部的给药通道，药物通过给药通道穿透皮肤至肝部位置，实现了通过皮肤给药实现肝部疾病的治疗，肝部疾病为体内器官，通过皮肤给药实现肝部疾病的治疗，实现了内病外治。
图1为本申请提供的一种皮肤给药控制方法的流程图，如图1所示，该方法包括：
S101：确定给药病种特征数据；
给药病种特征数据为用于表示待给药治疗病症的特征数据，给药病种特征数据为通过人机交互获得的用于描述待给药治疗病症的数据，包括基于人机交互获得的不同形式的给药病种特征数据，如病历文档、疾病图像(如CT图像等，舌苔图像，眼球图像等)、语音(如语音症状描述)，通过获取不同形式的给药病种特征数据，提高待给药治疗病症描述的准确性，以便在根据给药病种特征数据进行给药时，提高给药效率。
给药病种特征数据还可以为证/症，为用于表示病人患病后所出现的异常，包括通过人工交互获得的用于表示症状和体征的数据，如语音形式、文字形式或文档形式的症状和体征的数据。
S102：根据给药病种特征数据确定给药特征数据；
其中，给药特征数据包括给药经脉位置特征数据和给药药物数据，以便给药药物通过给药经脉位置与待治疗病症对应位置之间的经脉进行给药。通过皮 肤给药的方式进行给药治疗时，以便给药药物通过给药经脉位置与待治疗病症对应位置之间的经脉进行给药，根据给药特征数据确定皮肤给药位置和给药药物以实现给药时提高给药的精准性。
图2为本申请提供的一种皮肤给药控制方法的流程图，如图2所示，该方法包括：
S201：对给药病种特征数据进行识别，得到给药经脉特征数据；
给药经脉特征数据为用于表示治疗待给药治疗病症对应的经脉数据。经脉中医中指人体内气血运行的通路，经研究发现，组织液循环广泛存在人体，并形成遍布全身的组织液传输网络，人体组织液传输路径与穴位分布有密切联系。给药经脉特征数据为待给药治疗病症的病灶位置处的相关经脉，待给药治疗病症的病灶位置处组织液循环对应的中医经脉，举例说明，如，面瘫为由面神经麻痹或面神经损伤引起的疾病，属神经内科疾病，面瘫对应的经脉与督脉对应，督脉，行于背部正中，其脉多次与手足三阳经及阳维脉交会，能总督一身之阳经，督脉行于脊里，上行入脑。
遍历预设经脉给药数据库，判断预设经脉给药数据库中是否存在与给药病种特征数据对应的给药经脉特征数据，如果存在，得到给药经脉特征数据；如果不存在，对给药病种特征数据进行识别，得到病种核磁图像，其中，病种核磁图像为用于表示待给药治疗病症的核磁图像；对病种核磁图像进行基于图像分割识别的经脉特征提取处理，得到给药经脉特征数据。
预设经脉给药数据库中设置有疾病与给药经脉之间的映射关系，其中，同一疾病可以对应单一经脉，同一疾病也可以对应的多经脉，举例说明，如，肝腹水可以通过太阳膀胱经进行给药；肺部疾病对应肺经，可以通过肺经的上游经或下游经进行对肺部疾病的给药治疗。如果预设经脉给药数据库中不存在待给药治疗疾病对应的给药经脉之间的映射关系，通过获取待治疗病症中的核磁图像进行经脉特征数据的提取处理，得到给药经脉特征数据。
对病种核磁图像进行基于图像分割识别的经脉特征提取处理，包括：对病种核磁图像进行图像分割识别，得到核磁图像中病灶位置和病灶对应的组织液循环数据，根据组织液循环数据与包括十二经脉和奇经八脉的经脉进行匹配，得到给药经脉特征数据。
S202：根据给药经脉特征数据确定给药经脉位置特征数据；
给药经脉位置特征数据为用于表示给药位置的数据，给药经脉位置特征数据用于描述给药位置对应的穴位的位置数据，根据穴位与经脉之间的映射关系，根据给药经脉特征数据以及给药病种特征数据，确定进行皮肤给药的穴位位置。由于待治疗病症对应的经脉可以为单一经脉，也可以为多个经脉，对给药经脉特征数据进行识别，当识别待治疗病症对应的经脉为单一经脉时，根据该单一经脉和待治疗病症的治疗策略确定与单一经脉对应的给药穴位，举例说明，如，肝腹水可通过太阳膀胱经进行给药治疗，根据太阳膀胱经对应的多个穴位与治疗肝腹水的利尿治疗的治疗策略，确定属于太阳膀胱经的双肝腧穴、双肾腧穴的穴位处进行给药治疗。当识别待治疗病症对应的经脉为多个经脉时，根据多个经脉之间的上下游关系及交汇关系，并结合待治疗病症的治疗策略确定给药穴位，举例说明，如，肺部疾病，可通过肺经、肺经的上游经和下游经进行给药治疗，根据肺经、肺经的上游经和肺经的下游经以及该肺部疾病的治疗策略确定位于肺经、肺经的上游经和肺经的下游经上的多个穴位，分别在多个穴位处进行给药治疗。通过给药经脉确定进行皮肤给药的给药穴位位置，提高在给药时给药的精准性。
S203：在预设给药数据库中匹配与给药病种特征数据对应的给药药物数据；
给药药物数据为用于表示待给药药物的数据，根据给药病种特征数据进行给药药物数据的确定，给药药物数据为用于描述治疗待治疗病症的药物种类、剂量等数据。确定给药药物数据还包括：根据给药经脉位置特征数据和给药病种特征数据确定给药药物数据，其中，给药药物数据为用于表示不同给药位置处的药物种类及药物剂量。
S204：对给药经脉位置特征数据和给药药物数据进行给药特征生成处理，得到给药特征数据。
S103：根据给药特征数据控制给药单元在给药经脉位置提供药物穿透皮肤进行皮肤给药的动力。
图3为本申请提供的一种皮肤给药控制方法的流程图，如图3所示，该方法包括：
S301：对给药特征数据进行识别，得到给药经脉位置特征数据和给药药物数据；
给药药物数据还包括药物特征数据，药物特征数据为用于表示给药药物的 特征数据，包括用于表示药物组分和药物结构的数据，举例说明，如，给药药物的组分可以为单组分或多组分的药物，给药药物的结构可以为固体药物、液体药物或气体药。
S302：在预设给药数据库中匹配与给药经脉位置特征数据和给药药物数据对应的给药控制特征数据；
给药控制特征数据为用于表示控制药物穿透皮肤进行皮肤给药的动力的数据。给药经脉位置特征数据为用于表示进行皮肤给药的穴位位置，由于位置给药经脉位置特征数据对应的给药位置处的皮肤、对应穴位以及对应的病灶位置的不同，匹配与给药经脉位置特征数据对应的位置给药控制特征数据，匹配与给药药物数据对应的药物给药控制特征数据，根据位置给药控制特征数据和药物给药控制特征数据确定上述给药控制特征数据。给药控制特征数据为用于在给药过程中对给药单元的参数进行控制，包括给药温度和给药压力，以便基于给药温度和给药压力形成药物穿透皮肤进行皮肤给药的压力差。
S303：在给药经脉位置特征数据对应的给药经脉位置，给药单元承载给药药物数据对应的给药药物，根据给药控制特征数据控制给药单元与皮肤固定并提供药物穿透皮肤进行皮肤给药的动力。
在本申请的另一可选实施例中，提供了一种皮肤给药控制方法，该方法包括：
根据所述给药控制特征数据确定用于皮肤给药的给药控制参数，其中，控制参数包括第一控制参数和第二控制参数，第一控制参数和第二控制参数中的一个参数为压力控制参数，第一控制参数和第二控制参数中的另一个参数为温度控制参数；通过压力控制参数和温度控制参数对皮肤给药的压力差进行控制，压力差为穿透皮肤进行给药的压力差。
在本申请的一些可选实施例中，给药控制方法应用于设置有辅助给药单元和直接给药单元的给药装置中，给药控制方法包括：对压力控制参数进行识别，得到第一压力控制参数和第二压力控制参数；根据第一压力控制参数控制辅助给药单元生成第一压力，第一压力用于将给药装置固定于所述皮肤且形成密闭给药区域；根据第二压力控制参数控制直接给药单元生成第二压力，第一压力小于所述第二压力；以及根据温度控制参数控制直接给药单元生成给药温度，根据给药温度、第一压力和所述第二压力在密闭给药区域形成皮肤给药的压力 差。
在本申请的一些可选实施例中，给药温度、第一压力和第二压力在密闭给药区域形成皮肤给药的压力差包括：获取给药压力差数据，其中，给药压力差数据为用于表示密闭给药区域内压力差的数据；判断给药压力差数据是否满足预设给药压力差范围，如果不满足，生成更新压力控制参数，其中，根据更新压力控制参数确定更新第一压力数据和更新第二压力数据，直至给药压力差数据满足预设给药压力差范围；以及如果满足，在密闭给药区域内进行给药。
在本申请的一些可选实施例中，给药温度、第一压力和第二压力在密闭给药区域形成皮肤给药的压力差包括：获取给药压力差数据，其中，给药压力差数据为用于表示密闭区域内的压力差的数据；判断给药压力差数据是否满足预设给药压力差范围；如果不满足，生成更新温度控制参数，其中，根据温度控制参数确定更新温度，直至给药压力差满足预设给药压力差范围；如果满足，在密闭给药区域内进行给药。
在进行皮肤给药控制时，根据病种特征确定给药特征数据，根据给药特征数据确定不同给药位置及给药药物，其中，通过皮肤给药实现内病外治的方案的表达式为：S＝c(c1，c2，…cn)，ci＝f(va，vb，T)，其中，S表示当前给药病种的皮肤给药方案，ci为在进行给药病种的给药控制时，不同给药位置处的皮肤给药方案(包括给药位置、给药药物和给药控制参数)，其中，va和vb分别为给药单元中的第一压力单元和第二压力单元的控制参数，T为给药单元中温度单元的控制参数，通过对每个给药单元中va，vb，T进行控制，实现给药单元中的给药压力差的控制，提供药物穿透皮肤进行给药的动力。
在本申请的一个可选实施例中，给药单元包括直接给药单元和辅助给药单元，直接给药单元中设置有直接给药压力单元和温度单元，辅助给药单元中设置有辅助给药压力单元。辅助给药压力单元用于控制辅助给药单元生成第一压力，以实现给药单元与皮肤的固定并形成密闭给药区域，直接给药压力单元用于控制直接给药单元生成第二压力，温度单元控制直接给药单元生成给药温度，通过第一压力、第二压力和给药温度控制给药单元与皮肤形成的密闭给药区域内产生控制药物穿透皮肤进行给药的压力差。
通过压力控制参数和温度控制参数对皮肤给药的压力差进行控制，包括：根据给药控制特征数据确定与上述给药控制特征数据对应的给药控制模型，当 检测给药装置与皮肤接触，根据上述给药控制模型控制给药装置进行压力和温度的变化，通过设置在给药装置中的压力差检测元件对给药区域内的压力差进行检测，判断压力差数据是否满足上述给药控制模型对应的给药压力差范围，如果不满足，给药控制模型根据当前检测的压力差数据生成压力调整参数和温度调整参数，压力模块根据压力调整参数进行压力调整，温度模块根据温度调整参数进行温度调整，通过在给药过程中进行压力差的监测，并根据给药控制模型在监测得到的压力差数据的基础上进行反馈调节，控制给药区域内的温度差数据处于预设的给药压力差范围，进行皮肤给药。通过在给药装置中设置压力差检测元件对给药过程中进行反馈控制，通过设置将检测到的压力差数据与预设的给药压力差范围进行对比，在给药过程中实现对温度和压力的控制进而实现对给药压力差的控制，压力差形成药物穿透皮肤作用于病症位置处的动力，提高给药效率。
在本申请的另一可选实施例中，提供了一种皮肤给药控制方法，该方法包括：对给药特征数据进行识别，得到第一给药特征数据和第二给药特征数据，其中，第一给药特征数据为用于控制第一给药单元进行皮肤给药的给药特征数据，第二给药特征数据为用于控制第二给药单元进行皮肤给药的给药特征数据；对第一给药特征数据进行识别，得到第一给药经脉位置；对第二给药特征数据进行识别，得到第二给药经脉位置；根据第一给药特征数据控制第一给药单元在第一给药经脉位置提供药物穿透皮肤进行皮肤给药的动力；根据第二给药特征数据控制第二给药单元在第二给药经脉位置提供药物穿透皮肤进行皮肤给药的动力。
举例说明，如，在进行肝腹水的治疗时，根据给药特征数据确定分别在双肝腧穴、双肾腧穴进行给药，给药药物为活络化瘀药物，双肾腧穴，属足太阳膀胱经，肾可以调节人体的水液代谢，从而能够维持身体的正常运转。倘若是肾主水液的功能失调，则很容易出现水液停滞、小便不畅、尿遗、水肿等问题；双肝腧穴，属足太阳膀胱经穴，肝脏的水湿风气由此外输膀胱经，具有舒肝利胆、理气明目之效。第一给药单元在双肝腧穴进行给药，第二给药单元在双肾腧穴进行给药，控制分别位于双肝腧穴和双肾腧穴的位置处第一给药单元和第二给药单元提供给药药物穿透皮肤的动力，根据对第一给药单元和第二给药单元中的给药压力和温度参数的控制以实现对给药区域的压力差的控制。
举例说明，如，在进行面瘫的治疗时，根据给药特征数据确定分别在大椎穴、灵台穴进行给药，给药药物为活络化瘀药物，大椎是督脉和手、足三阳经的交会穴，上通于脑，有总督诸阳的作用，有解表通阳、清脑宁神之功效；灵台穴，属督脉，具有益气补阳之功效。第一给药单元在大椎穴进行给药，第二给药单元在灵台穴进行给药，控制分别位于大椎穴和灵台穴的位置处第一给药单元和第二给药单元提供给药药物穿透皮肤的动力，根据对第一给药单元和第二给药单元中的给药压力和温度参数的控制以实现对给药区域的压力差的控制。
在本申请的另一可选实施例中，提供了一种用于皮肤给药的给药装置，给药装置中可以设置1个给药单元、也可以设置多个给药单元；给药单元在进行给药时，对每个给药单元可以单独或者整体控制，控制给药单元中的给药压力差，包括控制给药的时间、压力、温度等，给药单元与云平台端通信连接，以实现与云平台端的信息交互。
图4为本申请提供的一种皮肤给药控制装置的结构示意图，如图4所示，该装置包括：
病种确定模块41，用于确定给药病种特征数据，其中，给药病种特征数据为用于表示待给药治疗病症的特征数据；
给药确定模块42，根据给药病种特征数据确定给药特征数据，其中，给药特征数据包括给药经脉位置特征数据和给药药物数据，以便给药药物通过给药经脉位置与待治疗病症对应位置之间的经脉进行给药；
控制给药模块43，根据给药特征数据控制给药单元在给药经脉位置提供药物穿透皮肤进行皮肤给药的动力。
图5为本申请提供的另一种皮肤给药控制装置的结构示意图，如图5所示，该装置包括：
病种识别模块51，用于对给药病种特征数据进行识别，得到给药经脉特征数据，其中，给药经脉特征数据为用于表示治疗待给药治疗病症对应的经脉数据；
给药位置确定模块52，用于根据给药经脉特征数据确定给药经脉位置特征数据，其中，给药经脉位置特征数据为用于表示给药位置的数据；
给药药物确定模块53，用于在预设给药数据库中匹配与给药病种特征数 据对应的所述给药药物数据，其中，给药药物数据为用于表示待给药药物的数据；以及
给药特征确定模块54，用于对给药经脉位置特征数据和给药药物数据进行给药特征生成处理，得到给药特征数据。
关于上述实施例中各单元的执行操作的具体方式已经在有关该方法的实施例中进行了详细描述，此处将不做详细阐述说明。
综上所述，在本申请中，通过控制药物以无创穿透皮肤的方式进行给药以实现内病外治的给药治疗，确定给药病种特征数据，根据所述给药病种特征数据确定包括给药经脉位置特征数据和给药药物数据的给药特征数据，根据给药特征数据控制给药单元在给药经脉位置处提供药物穿透皮肤进行皮肤给药的动力，通过根据待治疗病症确定进行皮肤给药的给药位置和给药药物，解决了现有技术中给药过程不精准的问题，实现了提高给药精准性和给药效率的技术效果。
需要说明的是，在附图的流程图示出的步骤可以在诸如一组计算机可执行指令的计算机系统中执行，并且，虽然在流程图中示出了逻辑顺序，但是在某些情况下，可以以不同于此处的顺序执行所示出或描述的步骤。
显然，本领域的技术人员应该明白，上述的本申请的各单元或各步骤可以用通用的计算装置来实现，它们可以集中在单个的计算装置上，或者分布在多个计算装置所组成的网络上，可选地，它们可以用计算装置可执行的程序代码来实现，从而，可以将它们存储在存储装置中由计算装置来执行，或者将它们分别制作成各个集成电路模块，或者将它们中的多个模块或步骤制作成单个集成电路模块来实现。这样，本申请不限制于任何特定的硬件和软件结合。
以上所述仅为本申请的优选实施例而已，并不用于限制本申请，对于本领域的技术人员来说，本申请可以有各种更改和变化。凡在本申请的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本申请的保护范围之内。

Claims (20)

  1. 一种皮肤给药控制方法，其特征在于，用于控制药物以无创穿透皮肤的方式进行给药以实现内病外治的给药治疗，应用于设置有给药单元的给药装置中，所述给药控制方法包括：
    确定给药病种特征数据，其中，所述给药病种特征数据为用于表示待给药治疗病症的特征数据；
    根据所述给药病种特征数据确定给药特征数据，其中，所述给药特征数据包括给药经脉位置特征数据和给药药物数据，以便给药药物通过给药经脉位置与待治疗病症对应位置之间的经脉进行给药；以及
    根据所述给药特征数据控制所述给药单元在给药经脉位置提供药物穿透皮肤进行皮肤给药的动力。
  2. 根据权利要求1所述的给药控制方法，其特征在于，根据所述给药病种特征数据确定给药特征数据包括：
    对所述给药病种特征数据进行识别，得到给药经脉特征数据，其中，所述给药经脉特征数据为用于表示治疗所述待给药治疗病症对应的经脉数据；
    根据所述给药经脉特征数据确定给药经脉位置特征数据，其中，所述给药经脉位置特征数据为用于表示给药位置的数据；
    在预设给药数据库中匹配与所述给药病种特征数据对应的所述给药药物数据，其中，所述给药药物数据为用于表示待给药药物的数据；以及
    对所述给药经脉位置特征数据和所述给药药物数据进行给药特征生成处理，得到所述给药特征数据。
  3. 根据权利要求2所述的给药控制方法，其特征在于，对所述给药病种特征数据进行识别，得到给药经脉特征数据包括：
    遍历预设经脉给药数据库，判断所述预设经脉给药数据库中是否存在与所述给药病种特征数据对应的给药经脉特征数据，如果存在，得到所述给药经脉特征数据；
    如果不存在，对所述给药病种特征数据进行识别，得到病种核磁图像，其中，所述病种核磁图像为用于表示待给药治疗病症的核磁图像；以及
    对所述病种核磁图像进行基于图像分割识别的经脉特征提取处理，得到所述给药经脉特征数据。
  4. 根据权利要求1所述的给药控制方法，其特征在于，根据所述给药特征数据控制所述给药单元在给药经脉位置提供药物穿透皮肤进行皮肤给药的动力包括：
    对所述给药特征数据进行识别，得到所述给药经脉位置特征数据和所述给药药物数据；
    在预设给药数据库中匹配与所述给药经脉位置特征数据和所述给药药物数据对应的给药控制特征数据，所述给药控制特征数据为用于表示控制药物穿透皮肤进行皮肤给药的动力的数据；以及
    在所述给药经脉位置特征数据对应的给药经脉位置，所述给药单元承载所述给药药物数据对应的给药药物，根据所述给药控制特征数据控制所述给药单元与皮肤固定并提供药物穿透皮肤进行皮肤给药的动力。
  5. 根据权利要求4所述的给药控制方法，其特征在于，根据所述给药控制特征数据控制所述给药单元与皮肤固定并提供药物穿透皮肤进行皮肤给药的动力包括：
    根据所述给药控制特征数据确定用于皮肤给药的给药控制参数，其中，所述控制参数包括第一控制参数和第二控制参数，所述第一控制参数和所述第二控制参数中的一个参数为压力控制参数，所述第一控制参数和所述第二控制参数中的另一个参数为温度控制参数；以及
    通过所述压力控制参数和所述温度控制参数对皮肤给药的压力差进行控制，所述压力差为穿透所述皮肤进行给药的压力差。
  6. 根据权利要求5所述的给药控制方法，其特征在于，所述给药控制方法应用于设置有辅助给药单元和直接给药单元的给药装置中，所述给药控制方法包括：
    对所述压力控制参数进行识别，得到第一压力控制参数和第二压力控制参数；
    根据所述第一压力控制参数控制所述辅助给药单元生成第一压力，所述第一压力用于将所述给药装置固定于所述皮肤且形成密闭给药区域；
    根据所述第二压力控制参数控制所述直接给药单元生成第二压力，所述第一压力小于所述第二压力；以及
    根据所述温度控制参数控制所述直接给药单元生成给药温度，所述给药温 度、所述第一压力和所述第二压力在所述密闭给药区域形成所述皮肤给药的压力差。
  7. 根据权利要求6所述的给药控制方法，其特征在于，所述给药温度、所述第一压力和所述第二压力在所述密闭给药区域形成所述皮肤给药的压力差包括：
    获取给药压力差数据，其中，所述给药压力差数据为用于表示所述密闭给药区域内压力差的数据；
    判断所述给药压力差数据是否满足预设给药压力差范围，
    如果不满足，生成更新压力控制参数，其中，根据所述更新压力控制参数确定更新第一压力数据和更新第二压力数据，直至所述给药压力差数据满足所述预设给药压力差范围；以及
    如果满足，在所述密闭给药区域内进行给药。
  8. 根据权利要求1所述的给药控制方法，其特征在于，所述给药装置包括第一给药单元和第二给药单元，根据所述给药特征数据控制所述给药单元在给药经脉位置提供药物穿透皮肤进行皮肤给药的动力包括：
    对所述给药特征数据进行识别，得到第一给药特征数据和第二给药特征数据，其中，所述第一给药特征数据为用于控制第一给药单元进行皮肤给药的给药特征数据，所述第二给药特征数据为用于控制第二给药单元进行皮肤给药的给药特征数据；
    对所述第一给药特征数据进行识别，得到第一给药经脉位置；
    对所述第二给药特征数据进行识别，得到第二给药经脉位置；
    根据所述第一给药特征数据控制所述第一给药单元在所述第一给药经脉位置提供药物穿透皮肤进行皮肤给药的动力；以及
    根据所述第二给药特征数据控制所述第二给药单元在所述第二给药经脉位置提供药物穿透皮肤进行皮肤给药的动力。
  9. 根据权利要求1所述的给药控制方法，其特征在于，
    根据所述给药病种特征数据确定给药经脉位置特征数据和给药药物数据的表达式为：S＝c(c1，c2，…cn)，ci＝f(va，vb，T)，其中，S表示所述给药病种特征数据对应的皮肤给药方案数据，ci为所述给药位置特征数据对应给药位置的皮肤给药方案数据，其中，所述给药位置特征数据对应给药位置的皮肤 给药方案数据包括给药位置数据、给药药物数据和给药控制参数数据，va和vb分别为给药单元中的第一压力单元和第二压力单元的控制参数，T为给药单元中温度单元的控制参数；根据给药单元中第一压力单元的控制参数、第二压力单元的控制参数和温度单元的控制参数确定给药压力差，压力差为穿透皮肤进行给药的压力差。
  10. 一种皮肤给药控制装置，其特征在于，用于控制药物以无创穿透皮肤的方式进行给药以实现内病外治的给药治疗，应用于设置有给药单元的给药装置中，所述给药控制装置包括：
    病种确定模块，用于确定给药病种特征数据，其中，所述给药病种特征数据为用于表示待给药治疗病症的特征数据；
    给药确定模块，根据所述给药病种特征数据确定给药特征数据，其中，所述给药特征数据包括给药经脉位置特征数据和给药药物数据，以便给药药物通过给药经脉位置与待治疗病症对应位置之间的经脉进行给药；以及
    控制给药模块，根据所述给药特征数据控制所述给药单元在给药经脉位置提供药物穿透皮肤进行皮肤给药的动力。
  11. 根据权利要求10所述的给药控制装置，其特征在于，给药确定模块包括：
    病种识别模块，用于对所述给药病种特征数据进行识别，得到给药经脉特征数据，其中，所述给药经脉特征数据为用于表示治疗所述待给药治疗病症对应的经脉数据；
    给药位置确定模块，用于根据所述给药经脉特征数据确定给药经脉位置特征数据，其中，所述给药经脉位置特征数据为用于表示给药位置的数据；
    给药药物确定模块，用于在预设给药数据库中匹配与所述给药病种特征数据对应的所述给药药物数据，其中，所述给药药物数据为用于表示待给药药物的数据；以及
    给药特征确定模块，用于对所述给药经脉位置特征数据和所述给药药物数据进行给药特征生成处理，得到所述给药特征数据。
  12. 根据权利要求11所述的给药控制装置，其特征在于，病种识别模块包括：
    给药经脉特征匹配模块，用于遍历预设经脉给药数据库，判断所述预设经 脉给药数据库中是否存在与所述给药病种特征数据对应的给药经脉特征数据，如果存在，得到所述给药经脉特征数据；
    如果不存在，对所述给药病种特征数据进行识别，得到病种核磁图像，其中，所述病种核磁图像为用于表示待给药治疗病症的核磁图像；以及
    对所述病种核磁图像进行基于图像分割识别的经脉特征提取处理，得到所述给药经脉特征数据。
  13. 根据权利要求10所述的给药控制装置，其特征在于，控制给药模块包括：
    给药特征识别模块，用于对所述给药特征数据进行识别，得到所述给药经脉位置特征数据和所述给药药物数据；
    给药控制特征匹配模块，用于在预设给药数据库中匹配与所述给药经脉位置特征数据和所述给药药物数据对应的给药控制特征数据，所述给药控制特征数据为用于表示控制药物穿透皮肤进行皮肤给药的动力的数据；以及
    给药控制模块，用于在所述给药经脉位置特征数据对应的给药经脉位置，所述给药单元承载所述给药药物数据对应的给药药物，根据所述给药控制特征数据控制所述给药单元与皮肤固定并提供药物穿透皮肤进行皮肤给药的动力。
  14. 根据权利要求13所述的给药控制装置，其特征在于，给药控制模块包括：
    控制参数确定模块，用于根据所述给药控制特征数据确定用于皮肤给药的给药控制参数，其中，所述控制参数包括第一控制参数和第二控制参数，所述第一控制参数和所述第二控制参数中的一个参数为压力控制参数，所述第一控制参数和所述第二控制参数中的另一个参数为温度控制参数；以及
    压力差模块，用于通过所述压力控制参数和所述温度控制参数对皮肤给药的压力差进行控制，所述压力差为穿透所述皮肤进行给药的压力差。
  15. 根据权利要求14所述的给药控制装置，其特征在于，所述给药控制方法应用于设置有辅助给药单元和直接给药单元的给药装置中，所述给药控制装置包括：
    控制参数识别模块，用于对所述压力控制参数进行识别，得到第一压力控制参数和第二压力控制参数；
    第一压力模块，用于根据所述第一压力控制参数控制所述辅助给药单元生 成第一压力，所述第一压力用于将所述给药装置固定于所述皮肤且形成密闭给药区域；
    第二压力模块，用于根据所述第二压力控制参数控制所述直接给药单元生成第二压力，所述第一压力小于所述第二压力；以及
    温度控制模块，用于根据所述温度控制参数控制所述直接给药单元生成给药温度；
    压力差给药模块，用于根据所述给药温度、所述第一压力和所述第二压力在所述密闭给药区域形成所述皮肤给药的压力差。
  16. 根据权利要求15所述的给药控制装置，其特征在于，压力差给药模块包括：
    压力差获取模块，用于获取给药压力差数据，其中，所述给药压力差数据为用于表示所述密闭给药区域内压力差的数据；
    压力差判断模块，用于判断所述给药压力差数据是否满足预设给药压力差范围，
    压力差控制模块，如果不满足，生成更新压力控制参数，其中，根据所述更新压力控制参数确定更新第一压力数据和更新第二压力数据，直至所述给药压力差数据满足所述预设给药压力差范围；以及
    如果满足，在所述密闭给药区域内进行给药。
  17. 根据权利要求10所述的给药控制装置，其特征在于，所述给药装置包括第一给药单元和第二给药单元，控制给药模块包括：
    给药识别模块，用于对所述给药特征数据进行识别，得到第一给药特征数据和第二给药特征数据，其中，所述第一给药特征数据为用于控制第一给药单元进行皮肤给药的给药特征数据，所述第二给药特征数据为用于控制第二给药单元进行皮肤给药的给药特征数据；
    第一给药位置识别模块，用于对所述第一给药特征数据进行识别，得到第一给药经脉位置；
    第二给药位置识别模块，用于对所述第二给药特征数据进行识别，得到第二给药经脉位置；
    第一给药模块，用于根据所述第一给药特征数据控制所述第一给药单元在所述第一给药经脉位置提供药物穿透皮肤进行皮肤给药的动力；以及
    第二给药模块，用于根据所述第二给药特征数据控制所述第二给药单元在所述第二给药经脉位置提供药物穿透皮肤进行皮肤给药的动力。
  18. 根据权利要求10所述的给药控制装置，其特征在于，
    给药确定模块，根据所述给药病种特征数据确定给药经脉位置特征数据和给药药物数据的表达式为：S＝c(c1，c2，…cn)，ci＝f(va，vb，T)，其中，S表示所述给药病种特征数据对应的皮肤给药方案数据，ci为所述给药位置特征数据对应给药位置的皮肤给药方案数据，其中，所述给药位置特征数据对应给药位置的皮肤给药方案数据包括给药位置数据、给药药物数据和给药控制参数数据，va和vb分别为给药单元中的第一压力单元和第二压力单元的控制参数，T为给药单元中温度单元的控制参数；根据给药单元中第一压力单元的控制参数、第二压力单元的控制参数和温度单元的控制参数确定给药压力差，压力差为穿透皮肤进行给药的压力差。
  19. 一种计算机可读存储介质，其特征在于，所述计算机可读存储介质存储有计算机指令，所述计算机指令用于使所述计算机执行权利要求1-9任意一项所述的皮肤给药控制方法。
  20. 一种电子设备，其特征在于，包括：至少一个处理器；以及与所述至少一个处理器通信连接的存储器；其中，所述存储器存储有可被所述至少一个处理器执行的计算机程序，所述计算机程序被所述至少一个处理器执行，以使所述至少一个处理器执行权利要求1-9任意一项所述的皮肤给药控制方法。
PCT/CN2023/092258 2022-07-28 2023-05-05 皮肤给药控制方法和装置 WO2024021740A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210895737.9 2022-07-28
CN202210895737.9A CN114949577B (zh) 2022-07-28 2022-07-28 皮肤给药控制装置

Publications (1)

Publication Number Publication Date
WO2024021740A1 true WO2024021740A1 (zh) 2024-02-01

Family

ID=82969936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/092258 WO2024021740A1 (zh) 2022-07-28 2023-05-05 皮肤给药控制方法和装置

Country Status (2)

Country Link
CN (2) CN114949577B (zh)
WO (1) WO2024021740A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114949576B (zh) * 2022-07-27 2022-11-11 北京神州汉方医药科技有限公司 用于皮肤给药的给药控制装置
CN114949577B (zh) * 2022-07-28 2022-11-11 北京神州汉方医药科技有限公司 皮肤给药控制装置

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN2671499Y (zh) * 2003-11-06 2005-01-19 张宏 实时检测及辅助诊断与治疗皮肤病性病的仪器
CN101284157A (zh) * 2007-04-11 2008-10-15 北京神州汉方医药科技有限公司 一种经皮给药装置
CN107016438A (zh) * 2017-04-14 2017-08-04 温川飙 一种基于中医辨证人工神经网络算法模型的系统
CN108355241A (zh) * 2018-01-30 2018-08-03 深圳市前海未来无限投资管理有限公司 一种透皮给药设备、装置及存储介质
CN109273079A (zh) * 2018-11-30 2019-01-25 广西小满科技有限公司 基于中医的ai云诊疗系统
CN109994178A (zh) * 2019-03-05 2019-07-09 南京邮电大学 基于医药箱的用药管理装置
CN112992344A (zh) * 2021-03-23 2021-06-18 杭州聪宝科技有限公司 一种中医智能辅助诊疗系统
CN113811609A (zh) * 2018-04-18 2021-12-17 卢遂显 一种检测和减轻人体内部炎症及预防癌症和心血管疾病的方法
CN114949577A (zh) * 2022-07-28 2022-08-30 北京神州汉方医药科技有限公司 皮肤给药控制方法和装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4400769C2 (de) * 1994-01-13 1996-07-18 Lohmann Therapie Syst Lts Verfahren und Vorrichtung zur Herstellung einer flächigen Darreichungsform mit einer Arzneimittelwirkstoffe enthaltenden Zubereitung
CN101615224A (zh) * 2008-06-27 2009-12-30 西门子公司 一种计算机辅助识别装置和系统
CN101744842A (zh) * 2008-12-01 2010-06-23 马德林 脂质体中药贴膜
CN101612092A (zh) * 2009-07-17 2009-12-30 孙雁群 一种粘贴式皮肤针治疗、给药装置
CN105877905A (zh) * 2016-03-30 2016-08-24 李复生 膏摩器
CN113616917B (zh) * 2021-07-12 2024-04-09 重庆医科大学 基于超声及微流控的智能经皮给药装置、方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN2671499Y (zh) * 2003-11-06 2005-01-19 张宏 实时检测及辅助诊断与治疗皮肤病性病的仪器
CN101284157A (zh) * 2007-04-11 2008-10-15 北京神州汉方医药科技有限公司 一种经皮给药装置
CN107016438A (zh) * 2017-04-14 2017-08-04 温川飙 一种基于中医辨证人工神经网络算法模型的系统
CN108355241A (zh) * 2018-01-30 2018-08-03 深圳市前海未来无限投资管理有限公司 一种透皮给药设备、装置及存储介质
CN113811609A (zh) * 2018-04-18 2021-12-17 卢遂显 一种检测和减轻人体内部炎症及预防癌症和心血管疾病的方法
CN109273079A (zh) * 2018-11-30 2019-01-25 广西小满科技有限公司 基于中医的ai云诊疗系统
CN109994178A (zh) * 2019-03-05 2019-07-09 南京邮电大学 基于医药箱的用药管理装置
CN112992344A (zh) * 2021-03-23 2021-06-18 杭州聪宝科技有限公司 一种中医智能辅助诊疗系统
CN114949577A (zh) * 2022-07-28 2022-08-30 北京神州汉方医药科技有限公司 皮肤给药控制方法和装置
CN115738057A (zh) * 2022-07-28 2023-03-07 北京神州汉方医药科技有限公司 用于内病外治的给药控制装置

Also Published As

Publication number Publication date
CN114949577B (zh) 2022-11-11
CN115738057A (zh) 2023-03-07
CN114949577A (zh) 2022-08-30

Similar Documents

Publication Publication Date Title
WO2024021740A1 (zh) 皮肤给药控制方法和装置
Chen et al. Acupuncture and the retrospect of its modern research
CN208741647U (zh) 一种分时段双囊多模式镇痛泵
WO2018166481A1 (zh) 一种闭环吸入麻醉控制系统
CN102552010A (zh) 三高康复理疗舱
Gao et al. Rehabilitation with a combination of scalp acupuncture and exercise therapy in spastic cerebral palsy
WO2024021739A1 (zh) 用于皮肤给药的给药控制方法及装置
Hu et al. Acupuncture for disorders of consciousness-A case series and review
Ali isMAil et al. Immediate fasting blood glucose response to electroacupuncture of ST36 versus CV12 in patients with type 2 diabetes mellitus: randomized controlled trial.
Li et al. Acupuncture with twirling reinforcing and reducing manipulation shows a control of hypertension and regulation of blood pressure-related target brain regions in spontaneously hypertensive rat: a preliminary resting-state functional MRI study
CN101862491A (zh) 无痛自动麻醉装置
CN201847986U (zh) 无痛自动麻醉装置
CN105213519A (zh) 一种治疗腰椎间盘突出、骨质增生的药物及其制备方法
US10765598B2 (en) Negative pressure device and methods thereof
US20230355976A1 (en) Neuromodulation for treatment of neonatal chronic hyperinsulinism
Liang et al. Observation on the Clinical Effect of Acupuncture and Moxibustion Combined with Repeated Transcranial Magnetic Stimulation on Facial Paralysis
Da et al. From Acupoints to Mylohyoid: Revealing the Neural Circuitry Basis of Electroacupuncture for Dysphagia
CN218739871U (zh) 电场发生装置
CN203220686U (zh) 低频脉冲经络调整装置
CN101579419B (zh) 一种治疗骨质增生的药酒
Jia Research on and Comparison of the Stimulating Peripheral Activity to Relieve Conditions and Acupuncture
CN105726967A (zh) 一种治疗麻醉术后神经损伤的中药制剂
Shieh et al. An enhanced patient controlled analgesia (EPCA) for the extracorporeal shock wave lithotripsy (ESWL)
CN201026345Y (zh) 男性不育症治疗系统
Wen et al. Clinical experience of Professor Shao Jing-ming: a master of acupuncture-moxibustion

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23844955

Country of ref document: EP

Kind code of ref document: A1